Serological subsets of juvenile idiopathic inflammatory myopathies - an update

References

• McCann LJ, Juggins AD, Maillard SM, et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland): clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford, England). 2006;45(10):1255–1260.
   PubMed Web of Science ®Google Scholar
• Shah M, Mamyrova G, Targoff IN, et al. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013;92(1):25–41.
   PubMed Web of Science ®Google Scholar
• Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol. 1995;34(8):732–736.
   PubMedGoogle Scholar
• Mendez EP, Lipton R, Ramsey-Goldman R, et al. US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum. 2003;49(3):300–305.
   PubMed Web of Science ®Google Scholar
• Ravelli A, Trail L, Ferrari C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res. 2010;62(1):63–72.
   PubMed Web of Science ®Google Scholar
• Bitnum S, Daeschner CW Jr, Travis LB, et al. Dermatomyositis. J Pediatr. 1964;64(1):101–131.
   PubMed Web of Science ®Google Scholar
• Huber AM, Mamyrova G, Lachenbruch PA, et al. Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies. Arthritis Care Res. 2014;66(5):732–740.
   PubMed Web of Science ®Google Scholar
• Hashkes PJ, Wright BM, Lauer MS, et al. Mortality outcomes in pediatric rheumatology in the US. Arthritis Rheum. 2010;62(2):599–608.
   PubMed Web of Science ®Google Scholar
• Rider LG, Lachenbruch PA, Monroe JB, et al. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum. 2009;60(11):3425–3435.
   PubMed Web of Science ®Google Scholar
• Sanner H, Sjaastad I, Flato B. Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool. Rheumatology (Oxford, England). 2014;53(9):1578–1585.
   PubMed Web of Science ®Google Scholar
• Bowyer SL, Blane CE, Sullivan DB, et al. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr. 1983;103(6):882–888.
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Campbell-Webster N, Ota S, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum. 2005;52(11):3570–3578.
   PubMed Web of Science ®Google Scholar
• Fisler RE, Liang MG, Fuhlbrigge RC, et al. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol. 2002;47(4):505–511.
   PubMed Web of Science ®Google Scholar
• Marie I, Hatron PY, Hachulla E, et al. Pulmonary involvement in polymyositis and in dermatomyositis. J Rheumatol. 1998;25(7):1336–1343.
   PubMed Web of Science ®Google Scholar
• Kang EH, Lee EB, Shin KC, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford, England). 2005;44(10):1282–1286.
   PubMed Web of Science ®Google Scholar
• Singh S, Suri D, Aulakh R, et al. Mortality in children with juvenile dermatomyositis: two decades of experience from a single tertiary care centre in North India. Clin Rheumatol. 2014;33(11):1675–1679.
   PubMed Web of Science ®Google Scholar
• Sanner H, Aalokken TM, Gran JT, et al. Pulmonary outcome in juvenile dermatomyositis: a case-control study. Ann Rheum Dis. 2011;70(1):86–91.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Higuchi K, Tamaki H, et al. Characteristics of juvenile dermatomyositis in Japan. Pediatrics Int. 1997;39(2):257–262.
   Google Scholar
• Tansley SL, Betteridge ZE, Shaddick G, et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology (Oxford, England). 2014;53(12):2204–2208.
   PubMed Web of Science ®Google Scholar
• Huber AM, Lang B, LeBlanc CM, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum. 2000;43(3):541–549.
   PubMed Web of Science ®Google Scholar
• Bingham A, Mamyrova G, Rother KI, et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore). 2008;87(2):70–86.
   PubMed Web of Science ®Google Scholar
• Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford, England). 2009;48(6):607–612.
   PubMed Web of Science ®Google Scholar
• Hoshino K, Muro Y, Sugiura K, et al. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford, England). 2010;49(9):1726–1733.
   PubMed Web of Science ®Google Scholar
• Rider LG, Shah M, Mamyrova G, et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013;92(4):223–243.
   PubMed Web of Science ®Google Scholar
• Deakin CT, Yasin SA, Arnold KA, et al. O44. An integrative analytical approach to subphenotyping of juvenile dermatomyositis. Rheumatology. 2015;54(suppl 1):i44.
   PubMed Web of Science ®Google Scholar
• Espada G, Maldonado Cocco JA, Fertig N, et al. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol. 2009;36(11):2547–2551.
   PubMed Web of Science ®Google Scholar
• Gunawardena H, Wedderburn LR, North J, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford, England). 2008;47(3):324–328.
   PubMed Web of Science ®Google Scholar
• Gunawardena H, Wedderburn LR, Chinoy H, et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum. 2009;60(6):1807–1814.
   PubMed Web of Science ®Google Scholar
• Kobayashi I, Okura Y, Yamada M, et al. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr. 2011;158(4):675–677.
   PubMed Web of Science ®Google Scholar
• Tansley SL, Betteridge ZE, Gunawardena H, et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther. 2014;16(4):R138.
   PubMed Web of Science ®Google Scholar
• Allenbach Y, Drouot L, Rigolet A, et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore). 2014;93(3):150–157.
   PubMed Web of Science ®Google Scholar
• Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991;70(6):360–374.
   PubMed Web of Science ®Google Scholar
• Wedderburn LR, McHugh NJ, Chinoy H, et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford, England). 2007;46(12):1786–1791.
   PubMed Web of Science ®Google Scholar
• Vancsa A, Gergely L, Ponyi A, et al. Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: relevance for clinical classification: retrospective study of 169 patients. Joint Bone Spine: Revue du Rhumatisme. 2010;77(2):125–130.
   PubMed Web of Science ®Google Scholar
• Rider LG, Miller FW, Targoff IN, et al. A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children. Arthritis Rheum. 1994;37(10):1534–1538.
   PubMed Web of Science ®Google Scholar
• Rouster-Stevens KA, Pachman LM. Autoantibody to signal recognition particle in African American girls with juvenile polymyositis. J Rheumatol. 2008;35(5):927–929.
   PubMed Web of Science ®Google Scholar
• Fujimoto M, Hamaguchi Y, Kaji K, et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum. 2012;64(2):513–522.
   PubMed Web of Science ®Google Scholar
• Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;71(5):710–713.
   PubMed Web of Science ®Google Scholar
• Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682–3689.
   PubMed Web of Science ®Google Scholar
• Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1gamma antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72(3):449–455.
   PubMed Web of Science ®Google Scholar
• Shah M, Targoff IN, Rice MM, et al. Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis. Arthritis Rheum. 2013;65(7):1934–1941.
   PubMed Web of Science ®Google Scholar
• Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60(7):2193–2200.
   PubMed Web of Science ®Google Scholar
• Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52(5):1571–1576.
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Takezaki S, Kobayashi I, et al. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology (Oxford, England). 2015;54(5):784–791.
   PubMed Web of Science ®Google Scholar
• Hall JC, Casciola-Rosen L, Samedy LA, et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res. 2013;65(8):1307–1315.
   PubMed Web of Science ®Google Scholar
• Fiorentino D, Chung L, Zwerner J, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65(1):25–34.
   PubMed Web of Science ®Google Scholar
• Almeida B, Campanilho-Marques R, Arnold K, et al. Analysis of published criteria for clinically inactive disease in a large juvenile dermatomyositis cohort shows that skin disease is underestimated. Arthritis Rheumatol. 2015;67:2495–2502.
   PubMed Web of Science ®Google Scholar
• Miller FW, Cooper RG, Vencovsky J, et al. Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum. 2013;65(12):3239–3247.
   PubMed Web of Science ®Google Scholar
• Gono T, Kawaguchi Y, Kuwana M, et al. Brief report: association of HLA-DRB1*0101/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum. 2012;64(11):3736–3740.
   PubMed Web of Science ®Google Scholar
• Chen Z, Hu W, Wang Y, et al. Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis/dermatomyositis. Clin Rheumatol. 2015;34:1627–1631.
   PubMed Web of Science ®Google Scholar
• Muro Y, Sugiura K, Hoshino K, et al. Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan. Arthritis Res Ther. 2011;13(6):R214.
   PubMed Web of Science ®Google Scholar
• Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63(3):713–721.
   PubMed Web of Science ®Google Scholar
• Betteridge ZE, Gunawardena H, McHugh NJ. Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. Arthritis Res Ther. 2011;13(2):209.
   PubMed Web of Science ®Google Scholar
• Betteridge ZE, Gunawardena H, Chinoy H, et al. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis. 2009;68(10):1621–1625.
   PubMed Web of Science ®Google Scholar
• Rutjes SA, Vree Egberts WT, Jongen P, et al. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol. 1997;109(1):32–40.
   PubMed Web of Science ®Google Scholar
• Tansley S, Gunawardena H. The evolving spectrum of polymyositis and dermatomyositis – moving towards clinicoserological syndromes: a critical review. Clin Rev Allergy Immunol. 2014;47(3):264–273.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Oddis CV, Goudeau D, et al. Anti-signal recognition particle autoantibody ELISA validation and clinical associations. Rheumatology (Oxford, England). 2015;54(7):1194–1199.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Oddis CV, Goudeau D, et al. Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validation. Rheumatology (Oxford, England). 2014;53(3):433–437.
   PubMed Web of Science ®Google Scholar
• Ghirardello A, Rampudda M, Ekholm L, et al. Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology (Oxford, England). 2010;49(12):2370–2374.
   PubMed Web of Science ®Google Scholar
• Ronnelid J, Barbasso Helmers S, Storfors H, et al. Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies. Autoimmun Rev. 2009;9(1):58–61.
   PubMed Web of Science ®Google Scholar
• Drouot L, Allenbach Y, Jouen F, et al. Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies. Arthritis Res Ther. 2014;16(1):R39.
   PubMed Web of Science ®Google Scholar
• Musset L, Miyara M, Benveniste O, et al. Analysis of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme A reductase using different technologies. J Immunol Res. 2014;2014:405956.
   Google Scholar
• Hane H, Muro Y, Watanabe K, et al. Establishment of an ELISA to detect anti-glycyl-tRNA synthetase antibody (anti-EJ), a serological marker of dermatomyositis/polymyositis and interstitial lung disease. Clin Chim Acta. 2014;431:9–14.
   PubMed Web of Science ®Google Scholar
• Nakashima R, Imura Y, Hosono Y, et al. The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia. PLoS One. 2014;9(1):e85062.
   PubMed Web of Science ®Google Scholar
• Koga T, Fujikawa K, Horai Y, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford, England). 2012;51(7):1278–1284.
   PubMed Web of Science ®Google Scholar
• Muro Y, Sugiura K, Akiyama M. Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Clin Rheumatol. 2013;32(3):395–398.
   PubMed Web of Science ®Google Scholar
• Stone KB, Oddis CV, Fertig N, et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum. 2007;56(9):3125–3131.
   PubMed Web of Science ®Google Scholar
• Muro Y, Sugiura K, Hoshino K, et al. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology (Oxford, England). 2012;51(5):800–804.
   PubMed Web of Science ®Google Scholar
• Gono T, Sato S, Kawaguchi Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford, England). 2012;51(9):1563–1570.
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Takezaki S, Kobayashi I, et al. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology (Oxford, England). 2015;54(5):784–91.
   PubMed Web of Science ®Google Scholar
• Sato S, Kobayashi N, Yamazaki K, et al. Clinical utility of anti-CADM-140/melanoma differentiated associated gene 5 autoantibody titres in patients with juvenile dermatomyositis and rapidly progressive interstitial lung disease. American College of Rheumatology 76th Annual Meeting; 2012 Nov; Washington, DC: Arthritis and Rheumatology. p. 292:S128.
   Google Scholar
• Tansley SL, Gunawardena H, Betteridge ZE, et al. O57. Autoantibody in juvenile dermatomyositis reflects disease activity: results of a Pilot Study. Rheumatology. 2014;53(suppl 1):i54–i55.
   Google Scholar
• Sato S, Kuwana M, Fujita T, et al. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatology/Japan Rheum Assoc. 2013;23(3):496–502.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Bandos A, Reed AM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile Dermatomyositis and adult polymyositis. Arthritis Rheumatol. 2014;66(3):740–749.
   PubMed Web of Science ®Google Scholar